Welcome to our dedicated page for THERIVA BIOLOGICS news (Ticker: TOVX), a resource for investors and traders seeking the latest updates and insights on THERIVA BIOLOGICS stock.
Theriva Biologics, Inc. (NYSE American: TOVX) is a clinical-stage company whose news flow centers on the development of therapeutics for cancer and related diseases. The company regularly issues updates on its lead oncolytic adenovirus candidate VCN-01 (zabilugene almadenorepvec), including clinical trial results, regulatory interactions, and presentations at major medical congresses.
Investors following TOVX news can expect coverage of data from the VIRAGE Phase 2b trial in metastatic pancreatic ductal adenocarcinoma, where Theriva has reported improved overall survival, progression free survival, and duration of response for patients treated with VCN-01 plus gemcitabine/nab-paclitaxel compared with standard-of-care alone. News also highlights regulatory milestones such as scientific advice from the European Medicines Agency’s Committee for Medicinal Products for Human Use on the design of a proposed Phase 3 trial, and company plans to discuss pivotal trial protocols with regulators.
Theriva’s releases also describe progress in retinoblastoma, including Phase 1 safety and clinical outcome data for intravitreal VCN-01 in refractory pediatric patients, as well as preclinical developments from the VCN-X discovery program, such as VCN-12. Beyond oncology, news items cover SYN-004 (ribaxamase) data in allogeneic hematopoietic cell transplant recipients and its potential role in protecting the gut microbiome and reducing acute graft-versus-host disease.
Additional TOVX news includes quarterly operational and financial updates, public offerings and warrant transactions, at-the-market equity programs, and proxy-related matters tied to share issuance approvals. This page aggregates these disclosures so readers can review Theriva’s clinical, regulatory, and financing developments in one place and track how its pipeline and capital strategy evolve over time.
Theriva Biologics (TOVX) will host a conference call on November 10, 2022, at 8:30 a.m. ET, to discuss its financial results for Q3 2022, ending September 30. The call will provide a corporate update, with live participation available via phone or online. The company specializes in developing therapeutics for cancer and related diseases, including innovative treatments like VCN-01, SYN-004, and SYN-020. For further details, visit their website.
Theriva Biologics (TOVX) announced the dosing of the first patient in Cohort 2 of its ongoing Phase 1b/2a clinical trial for SYN-004, aimed at preventing acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients. Following a positive safety review of Cohort 1 by an independent committee, the trial will assess SYN-004’s safety and pharmacokinetics while evaluating its protective effects on the gut microbiome. The trial is expected to enroll up to 36 participants, advancing therapeutic options for patients with hematologic cancers.
Theriva Biologics (NYSE American: TOVX) announced a KOL webinar on November 7, 2022, at 11 a.m. ET, featuring experts Michael Aaron Morse, M.D., and Arsen Osipov, M.D. The discussion will focus on the oncolytic virus landscape and data supporting the Company’s novel oncolytic adenovirus platform for treating cancers with high unmet needs, specifically pancreatic ductal adenocarcinoma (PDAC). The upcoming Phase 2 trial, VIRAGE, will evaluate VCN-01 combined with standard chemotherapy. A live Q&A will follow the presentation.
Theriva Biologics (TOVX) announced an oral presentation highlighting the encouraging biological activity of VCN-01 in combination with durvalumab at the 14th International Oncolytic Virotherapy Conference in Japan. The Phase 1 study focuses on patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC). The presentation, scheduled for October 25, 2022, will be delivered by COO Frank Tufaro. This research may support further development of VCN-01 as a viable treatment option in oncology.
Theriva Biologics, formerly known as Synthetic Biologics, Inc. (NYSE American: TOVX), announced a rebranding to reflect its focus on developing innovative oncolytic viruses for cancer treatment. The new branding will be visible with the stock trading under the ticker symbol TOVX starting October 13, 2022. The company highlighted its lead clinical program, VCN-01, aimed at improving tumor treatment, alongside the preclinical program VCN-11. Theriva aims to significantly impact patients with high unmet needs through its advanced therapies, reinforcing its commitment to addressing challenging cancers.